tiprankstipranks
Trending News
More News >
Pluri (PLUR)
NASDAQ:PLUR

Pluri (PLUR) Price & Analysis

Compare
975 Followers

PLUR Stock Chart & Stats

$3.45
-$0.22(-4.74%)
At close: 4:00 PM EST
$3.45
-$0.22(-4.74%)

Pluri News

PLUR FAQ

What was Pluri’s price range in the past 12 months?
Pluri lowest stock price was $2.82 and its highest was $7.13 in the past 12 months.
    What is Pluri’s market cap?
    Pluri’s market cap is $29.80M.
      When is Pluri’s upcoming earnings report date?
      The company’s upcoming earnings report date is not yet available.
      How were Pluri’s earnings last quarter?
      Currently, no data Available
      Is Pluri overvalued?
      According to Wall Street analysts Pluri’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
        Does Pluri pay dividends?
        Pluri does not currently pay dividends.
        What is Pluri’s EPS estimate?
        Pluri’s EPS estimate for its next earnings report is not yet available.
        How many shares outstanding does Pluri have?
        Pluri has 9,253,897 shares outstanding.
          What happened to Pluri’s price movement after its last earnings report?
          Currently, no data Available
          Which hedge fund is a major shareholder of Pluri?
          Currently, no hedge funds are holding shares in PLUR
          What is the TipRanks Smart Score and how is it calculated?
          Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

            Company Description

            Pluri

            Pluri (PLUR) is a biotechnology company focused on developing innovative therapies based on its proprietary technology platform for cell reprogramming and stem cell biology. Operating primarily in the healthcare and life sciences sectors, Pluri specializes in creating novel treatments for various diseases, particularly in regenerative medicine and immunotherapy. The company aims to harness the potential of pluripotent stem cells to address unmet medical needs and improve patient outcomes through advanced cellular therapies.

            Pluri (PLUR) Earnings & Revenues

            Similar Stocks
            Company
            Price & Change
            Follow
            IGC Pharma
            Iterum Therapeutics
            PolyPid
            AN2 Therapeutics, Inc.

            Ownership Overview

            20.47%0.03%0.13%79.12%
            20.47% Insiders
            0.13% Other Institutional Investors
            79.12% Public Companies and
            Individual Investors

            Options Prices

            Currently, No data available
            ---
            Popular Stocks